Skip to main content
GutCited

Bifidobacterium lactis pour Chronic Constipation

B

Dose-dependently reduces whole gut transit time (WGTT). Higher dose (17.2 billion CFU) showed 31% reduction in WGTT. Also reduces functional GI symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dlactis\u0026condition\u003Dconstipation'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

Dose-dependently reduces whole gut transit time (WGTT). Higher dose (17.2 billion CFU) showed 31% reduction in WGTT. Also reduces functional GI symptoms.

Key Study Findings

Randomized Controlled Trial 8 weeks Double-blind
Effect of an 8-Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi-Center, Triple-Blind, Randomized, …
Dose: None vs: Placebo Outcome: Complete spontaneous bowel movements (CSBMs) Effet: None None

Population: Adults with functional constipation (Rome III)

Randomized Controlled Trial n=67 4 weeks Double-blind
Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with …
Dose: None vs: Placebo Outcome: Weekly spontaneous bowel movements Effet: 4.94 vs 3.00 (P<0.001) P<0.001

Population: Older adults >=60 with functional constipation (Rome IV)

Randomized Controlled Trial n=35 12 weeks Double-blind
Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable …
Dose: None vs: Placebo Outcome: Gut barrier function (zonulin levels) Effet: Zonulin -19.5 ng/mL at week 16 p=0.0002 wk16; p=0.0053 grp

Population: IBS without constipation patients

Review
An update on probiotics in paediatrics.
Dose: None vs: None Outcome: GI disorder outcomes in paediatrics Effet: None None

Population: Paediatric patients with GI disorders

In Vitro n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL vs: IBS supernatants without probiotic Outcome: Caco-2 paracellular permeability Effet: None <0.001

Population: IBS patients (28) and asymptomatic controls (7)

Randomized Controlled Trial n=128 2 weeks Double-blind
Probiotics and Fever Duration in Children With Upper Respiratory Tract Infections: A Randomized Clinical Trial.
Dose: 0.5 mL daily for 14 days vs: Placebo Outcome: Fever duration (days) Effet: RR 0.64 (95% CI 0.51-0.80) None

Population: Children 28 days-4 years with fever and URTI

Key Statistics

4

Études

600

Participants

Positive

B

Note

Referenced Papers

Current opinion in … 2025
Pediatric gastroenterology, hepatology … 2017 27 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
1-10 billion CFU/day
immunesupport:
5-10 billion CFU/day
constipationsupport:
17.2 billion CFU/day (HN019 strain, optimal dose)

Limite supérieure : Well-tolerated up to 17.2 billion CFU/day in clinical trials

Posologies étudiées dans la recherche

Posologie Durée Effet N
None 8 weeks Neutral --
None 4 weeks Positive 67
None 12 weeks Positive 35
None -- Positive --
1e6 CFU/mL -- Positive 35
0.5 mL daily for 14 days 2 weeks Positive 128
None 2 weeks Negative 117
10 g 4 weeks Positive --

Moment optimal de prise : With or without food; morning dosing may be optimal for transit effects

Safety & Side Effects

Effets indésirables signalés

  • Mild gas and bloating during initial use
  • Occasional abdominal discomfort
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

Interactions connues

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Apport maximal tolérable : Well-tolerated up to 17.2 billion CFU/day in clinical trials

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Bifidobacterium lactis help with Chronic Constipation?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium lactis may support Chronic Constipation management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium lactis should I take for Chronic Constipation?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium lactis?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium lactis and Chronic Constipation?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.

Related Evidence

Autres ingrédients pour Chronic Constipation

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.